What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
Capdevila, Jaume
What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer? [electronic resource] - Critical reviews in oncology/hematology Nov 2014 - 83-106 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1879-0461
10.1016/j.critrevonc.2014.05.004 doi
Antineoplastic Agents--therapeutic use
Colorectal Neoplasms--drug therapy
Humans
Indoles--therapeutic use
Receptors, Fibroblast Growth Factor--antagonists & inhibitors
Receptors, Platelet-Derived Growth Factor--antagonists & inhibitors
Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors
Signal Transduction--drug effects
What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer? [electronic resource] - Critical reviews in oncology/hematology Nov 2014 - 83-106 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1879-0461
10.1016/j.critrevonc.2014.05.004 doi
Antineoplastic Agents--therapeutic use
Colorectal Neoplasms--drug therapy
Humans
Indoles--therapeutic use
Receptors, Fibroblast Growth Factor--antagonists & inhibitors
Receptors, Platelet-Derived Growth Factor--antagonists & inhibitors
Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors
Signal Transduction--drug effects